SCHEMBL452784

SCHEMBL452784

COc1ccc(-n2c(C(C)N(C)S(=O)(=O)c3ccc(-c4ccccc4)cc3)nc3cccc(C)c3c2=O)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.44
RAB9A P51151 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
CXCR3 P49682 3/20 0.42
PIK3CD O00329 3/20 0.41
G6PD P11413 1/20 0.40
C1R P00736 1/20 0.39
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
USP2 O75604 1/20 0.38
CYP1A2 P05177 1/20 0.38
CASP1 P29466 1/20 0.38
BRCA1 P38398 1/20 0.38
CASP7 P55210 1/20 0.38
HBB P68871 1/20 0.38
HSD17B10 Q99714 1/20 0.38
OXTR P30559 1/20 0.38
KCNH2 Q12809 1/20 0.37
HRH3 Q9Y5N1 1/20 0.37
LMNA P02545 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL452305 0.95 CXCR3 (0.41) ALDH1A1RAB9ANPSR1CXCR3PIK3CD
SCHEMBL450632 0.92 ALDH1A1 (0.42) ALDH1A1RAB9ANPSR1CXCR3PIK3CD
SCHEMBL447897 0.91 ALDH1A1 (0.42) ALDH1A1RAB9ANPSR1CXCR3PIK3CD
SCHEMBL448724 0.90 NPBWR1 (0.40) ALDH1A1CXCR3PIK3CDC1RKCNH2
SCHEMBL451645 0.89 CXCR3 (0.38) ALDH1A1RAB9ANPSR1CXCR3PIK3CD
SCHEMBL453148 0.88 CXCR3 (0.44) ALDH1A1CXCR3PIK3CDKCNH2HRH3
SCHEMBL452865 0.86 ALDH1A1 (0.46) ALDH1A1RAB9ANPSR1CXCR3G6PD
SCHEMBL452063 0.86 CXCR3 (0.44) ALDH1A1NPSR1CXCR3PIK3CDMEN1
SCHEMBL450015 0.85 ALDH1A1 (0.46) ALDH1A1RAB9ANPSR1CXCR3G6PD
SCHEMBL450081 0.84 ALDH1A1 (0.48) ALDH1A1RAB9ANPSR1CXCR3G6PD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120064025-A1 Quinazolinone Modulators Of Nuclear Receptors EXELIXIS, INC. (US) 2012-03-15 US claimed
EP-1521746-B1 QUINAZOLINONE MODULATORS OF NUCLEAR RECEPTORS X CEPTOR THERAPEUTICS INC (US) 2011-04-27 EP claimed
US-20120064025-A1 Quinazolinone Modulators Of Nuclear Receptors EXELIXIS, INC. (US) 2012-03-15 US disclosed
EP-1521746-B1 QUINAZOLINONE MODULATORS OF NUCLEAR RECEPTORS X CEPTOR THERAPEUTICS INC (US) 2011-04-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120064025-A1 Quinazolinone Modulators Of Nuclear Receptors NR1H4, NR1H2, NR1H3 ALDH1A1 3161/4885RAB9A 1349/4885NPSR1 388/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.